Science
Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug – Mirage News
Waisman Biomanufacturing at the University of Wisconsin-Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by…
Waisman Biomanufacturing at the University of Wisconsin-Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen.
The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.
“Our miss…
-
Noosa News16 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News14 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News23 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common
-
Noosa News21 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up